Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer

BACKGROUND: Inducible activation of nuclear factor (NF)-κB is one of the principal mechanisms through which resistant prostate cancer cells are protected from radiotherapy. We hypothesised that inactivation of inducible NF-κB with a novel NF-κB inhibitor, DHMEQ, would increase the therapeutic effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozakai, N, Kikuchi, E, Hasegawa, M, Suzuki, E, Ide, H, Miyajima, A, Horiguchi, Y, Nakashima, J, Umezawa, K, Shigematsu, N, Oya, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419964/
https://www.ncbi.nlm.nih.gov/pubmed/22805327
http://dx.doi.org/10.1038/bjc.2012.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419964/
https://www.ncbi.nlm.nih.gov/pubmed/22805327
http://dx.doi.org/10.1038/bjc.2012.321

Ejemplares similares